Sjögren syndrome

Comprehensive Ophthalmology Update

Volumn 8, Issue 4, 2007, Pages 205-212

  Srinivasan, Sathish ^a,b   Slomovic, Allan R ^a,b  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Autoimmune disease; Dry eye; Dry mouth; Sj gren

Indexed keywords

ANTIINFLAMMATORY AGENT; ARTIFICIAL TEAR; BOTULINUM TOXIN; CEVIMELINE; CORTICOSTEROID; CYCLOSPORIN A; DIQUAFOSOL; FIBRONECTIN; PILOCARPINE; RETINOL; STEROID;

CLINICAL FEATURE; CYTOTOXICITY; DRY EYE; HUMAN; PATHOGENESIS; PATIENT COUNSELING; PREVALENCE; PTOSIS; REVIEW; SJOEGREN SYNDROME;

ANTI-INFLAMMATORY AGENTS; AUTOIMMUNITY; DIAGNOSIS, DIFFERENTIAL; HUMANS; OPHTHALMIC SOLUTIONS; PROGNOSIS; SJOGREN'S SYNDROME;

EID: 36749082929     PISSN: 15277313     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Sjögren HS: [Zur kenntnis der keratoconjunctivitis sicca (Keratitis folliformis bei hypofunktion der tranendrusen).] (German) Acta Ophthalmol (Copenh) 11: 1-151, 1933
2. Morgan WS, Castleman B: A clinicopathologic study of Mikulicz's disease. Am J Pathol 29: 471-503, 1953
3. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ: Sjoegren's syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine (Baltimore) 44: 187-231, 1965
4. Silman AJ, Rooney BK: Epidemiology of Sjögren's syndrome, in Eriksson P, Jonsson R (eds): The 100-year Anniversary of Henrik Sjögren. Hygiea 108, 1999, pp 53-7
5. Pillemer SR, Matteson EL, Jacobsson LT, et al: Incidence of physician-diagnosed primary Sjögren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 76: 593-9, 2001
6. Reveille JD, Wilson RW, Provost TT, et al: Primary Sjögren's syndrome and other autoimmune diseases in families. Prevalence and immunogenetic studies in six kindreds. Ann Intern Med 101: 748-56, 1984
7. Nepom GT: MHC and autoimmune diseases. Immunol Ser 59: 143-64, 1993
8. Reveille JD: The molecular genetics of systemic lupus erythematosus and Sjögren's syndrome. Curr Opin Rheumatol 4: 644-56, 1992
9. Bolstad AI, Jonsson R: Genetic aspects of Sjögren's syndrome. Arthritis Res 4: 353-9, 2002
10. Manthorpe R, Morling N, Platz P, et al: HLA-D antigen frequencies in Sjögren's syndrome. Differences between the primary and secondary form. Scand J Rheumatol 10: 124-8, 1981
11. Papasteriades CA, Skopouli FN, Drosos AA, et al: HLA-alloantigen associations in Greek patients with Sjögren's syndrome. J Autoimmun 1: 85-90, 1988
12. Uhlig T, Kvien TK, Jensen JL, et al: Sicca symptoms, saliva and tear production, and disease variables in 636 patients with rheumatoid arthritis. Ann Rheum Dis 58: 415-22, 1999
13. Arnett FC: HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol 12: 107-28, 1995
14. Nagata Y, Inoue H, Yamada K, et al: Activation of Epstein-Barr virus by saliva from Sjogren's syndrome patients. Immunology 111: 223-9, 2004
15. Triantafyllopoulou A, Tapinos N, Moutsopoulos HM: Evidence for coxsackievirus infection in primary Sjögren's syndrome. Arthritis Rheum 50: 2897-902, 2004
16. Mackay F, Browning JL: BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2: 465-75, 2002
17. Stohl W: Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders. Expert Opin Ther Targets 8: 177-89, 2004
18. Mackay F, Sierro F, Grey ST, et al: The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 8: 243-65, 2005
19. Lavie F, Miceli-Richard C, Quillard J, et al: Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. J Pathol 202: 496-502, 2004
20. Groom J, Kalled SL, Cutler AH, et al: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 109: 59-68, 2002
21. Mariette X, Roux S, Zhang J, et al: The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 62: 168-71, 2003
22. Fox RI, Michelson P, Casiano CA, et al: Sjögren's syndrome. Clin Dermatol 18: 589-600, 2000
23. Daniels TE, Fox PC: Salivary and oral components of Sjögren's syndrome. Rheum Dis Clin North Am 18: 571-89, 1992
24. Vitali C, Bombardieri S, Jonsson R, et al: Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61: 554-8, 2002
25. Nusair S, Rubinow A: The use of oral pilocarpine in xerostomia and Sjögren's syndrome. Semin Arthritis Rheum 28: 360-7, 1999
26. Ono M, Takamura E, Shinozaki K, et al: Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study. Am J Ophthalmol 138: 6-17, 2004
27. Kassan SS, Thomas TL, Moutsopoulos HM, et al: Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89: 888-92, 1978
28. Voulgarelis M, Dafni UG, Isenberg DA, et al: Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum 42: 1765-72, 1999
29. Schein OD, Tielsch JM, Munõz B, et al: Relation between signs and symptoms of dry eye in the elderly. A population-based perspective. Ophthalmology 104: 1395-401, 1997
30. Hay EM, Thomas E, Pal B, et al: Weak association between subjective symptoms or and objective testing for dry eyes and dry mouth: results from a population based study. Ann Rheum Dis 57: 20-4, 1998
31. McCarty CA, Bansal AK, Livingston PM, et al: The epidemiology of dry eye in Melbourne, Australia. Ophthalmology 105: 1114-9, 1998
32. Schein OD, Muñoz B, Tielsch JM, et al: Prevalence of dry eye among the elderly. Am J Ophthalmol 124: 723-8, 1997
33. Bjerrum KB: Test and symptoms in keratoconjunctivitis sicca and their correlation. Acta Ophthalmol Scand 74: 436-41, 1996
34. Da Dalt S, Moncada A, Priori R, et al: The lactoferrin tear test in the diagnosis of Sjögren's syndrome. Eur J Ophthalmol 6: 284-6, 1996
35. Versura P, Frigato M, Mulé R et al: A proposal of new ocular items in Sjögren's syndrome classification criteria. Clin Exp Rheumatol 24: 567-72, 2006
36. Korb DR: Survey of preferred tests for diagnosis of the tear film and dry eye. Cornea 19: 483-6, 2000
37. Nichols KK, Nichols JJ, Zadnik K: Frequency of dry eye diagnostic test procedures used in various modes of ophthalmic practice. Cornea 19: 477-82, 2000
38. Begley CG, Chalmers RL, Abetz L, et al: The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 44: 4753-61, 2003
39. Kervick GN, Pflugfelder SC, Haimovici R, et al: Paracentral rheumatoid corneal ulceration. Clinical features and cyclosporine therapy. Ophthalmology 99: 80-8, 1992
40. Musch DC, Sugar A, Meyer RF: Demographic and predisposing factors in corneal ulceration. Arch Ophthalmol 101: 1545-8, 1983
41. Stevenson D, Tauber J, Reis BL: Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 107: 967-74, 2000
42. Sall K, Stevenson OD, Mundorf TK, et al: Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 107: 631-9, 2000
43. Marsh P, Pflugfelder SC: Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology 106: 811-6, 1999
44. Tabbara KF, Frayha RA: Alternate-day steroid therapy for patients with primary Sjögren's syndrome. Ann Ophthalmol 15: 358-61, 1983
45. Fischbarg J: Diquafosol tetrasodium. Inspire/Allergan/Santen. Curr Opin Investig Drugs 4: 1377-83, 2003
46. Nichols KK, Yerxa B, Kellerman DJ: Diquafosol tetrasodium: a novel dry eye therapy. Expert Opin Investig Drugs 13: 47-54, 2004
47. Tauber J, Davitt WF, Bokosky JE, et al: Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 23: 784-92, 2004
48. Kirkness CM, Adams GG, Dilly PN, et al: Botulinum toxin A-induced protective ptosis in corneal disease. Ophthalmology 95: 473-80, 1988
49. Fox RI: Sjögren's syndrome. Lancet 366: 321-31, 2005